Screener
Madrigal Pharmaceuticals, Inc. MDGL Total Revenue
Total Revenue at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Product revenue, net | $364,252 | $212,802 | $675,589 | $350,052 |
| Operating expenses: | ||||
| Cost of sales | 40,007 | 9,065 | 66,854 | 13,578 |
| Research and development | 91,178 | 54,081 | 199,870 | 98,253 |
| Selling, general and administrative | 289,375 | 196,858 | 557,896 | 364,734 |
| Total operating expenses | 420,560 | 260,004 | 824,620 | 476,565 |
| Loss from operations | (56,308) | (47,202) | (149,031) | (126,513) |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s total revenue?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported total revenue of $364.25M in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s total revenue changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s total revenue increased by 71.2% year-over-year, from $212.8M to $364.25M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude